Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 7:12:142.
doi: 10.1186/1477-7819-12-142.

Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer

Hao Zhang, Yuan Ren, Deyan Pang, Caigang Liu  1
Affiliations

Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer

Hao Zhang et al. World J Surg Oncol. .

Erratum in

Abstract

Background: We investigated the expression status of AGBL2 and its inhibitor latexin in breast cancer stem cells and its clinical implications in order to lay a foundation for managing breast cancer.

Methods: CD44+/CD24- tumor cells (CSC) from clinical specimens were sorted using flow cytometry. AGBL2 expression status was detected in CSC and 126 breast cancer specimens by western blot and immunohistochemistry staining. The relationship between the AGBL2 protein and clinicopathological parameters and prognosis was subsequently determined.

Result: As a result, CSC are more likely to generate new tumors in mice and cell microspheres that are deficient in non-obese diabetic/severe combined immunodeficiency mice (NOD/SCID) compared to the control group. The AGBL2 protein was expressed higher in CSC induced to epithelial to mesenchymal transition (EMT) when compared to the control cells, and was found to be related to CSC chemotherapy resistance. After Spearman regression correlation analysis, AGBL2 was observed to be related to clinical stage, histological stage, and lymph node metastasis. In the Cox regression test, the AGBL2 protein was detected as an independent prognostic factor. Through immunoprecipitation, AGBL2 and latexin could form immune complexes.

Conclusions: These results demonstrate that AGBL2 is a latexin-interacting protein that regulates the tubulin tyrosination cycle and is a potential target for intervention.

PubMed Disclaimer

Figures

Figure 1
Figure 1
AGBL2 protein was expressed significantly higher in breast cancer tissues (B) compared to paracancerous tissue and atypical hyperplasia tissues (A).
Figure 2
Figure 2
Survival curves about clinical stage (A), lymph node metastasis (B), and AGBL2 expression (C).
Figure 3
Figure 3
Cells exposed to AGBL2-siRNA or Latexin decreased among the three drugs when compared with the control (DDP: cisplatin, EPI: epirubicin, DTX: docetaxel, MTT: methylthiazolyldiphenyl-tetrazolium bromide, h: hours).
Figure 4
Figure 4
AGBL2 and Latexin could form immune complexes through immunoprecipitation (MW: Molecular Weight).
See this image and copyright information in PMC

References

    1. Gaffan J, Dacre J, Jones A. Educating undergraduate medical students about oncology: a literature review. J Clin Oncol. 2006;24:1932–1939. doi: 10.1200/JCO.2005.02.6617. - DOI - PubMed
    1. Dowling EC, Klabunde C, Patnick J. Ballard-Barbash R, for the International Cancer Screening Network (ICSN): Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen. 2010;17:139–146. doi: 10.1258/jms.2010.010033. - DOI - PubMed
    1. Dilaveri CA, Mac Bride MB, Sandhu NP, Neal L, Ghosh K, Wahner-Roedler DL. Breast manifestations of systemic diseases. Int J Womens Health. 2012;4:35–43. - PMC - PubMed
    1. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21:283–296. doi: 10.1016/j.ccr.2012.03.003. - DOI - PMC - PubMed
    1. Wang J, Cao MG, You CZ, Wang CL, Liu SL, Kai C, Dou J. A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer. Cell Mol Biol (Noisy-le-grand) 2012;58:OL1641–OL1645. - PubMed

Publication types

MeSH terms